Free Trial
ASX:PAB

Patrys (PAB) Stock Price, News & Analysis

Patrys logo

About Patrys Stock (ASX:PAB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
250,000 shs
Average Volume
N/A
Market Capitalization
$5.14 million
P/E Ratio
N/A
Dividend Yield
8.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Receive PAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

PAB Stock News Headlines

Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Patrys Limited AGM Resolutions Successfully Passed
Patrys Limited Shifts Focus to Promising PAT-DX3 Development
See More Headlines

PAB Stock Analysis - Frequently Asked Questions

Patrys Limited (ASX:PAB) announced its quarterly earnings data on Wednesday, February, 20th. The company reported $0.00 earnings per share for the quarter. Patrys had a negative net margin of 253.85% and a negative trailing twelve-month return on equity of 83.38%.

Company Calendar

Last Earnings
2/20/2019
Today
5/25/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:PAB
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,540,000.00
Net Margins
-253.85%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.39 million
Price / Cash Flow
2.40
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,060,000,000
Free Float
N/A
Market Cap
$5.14 million
Optionable
Not Optionable
Beta
0.42
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (ASX:PAB) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners